Coya Therapeutics, Inc. COYA
Set alert
As of Nov 2, 10:49 AM ET
- YTD
- -41.39%
- 1 year
- -46.21%
- Open
- 3.64
- Prev close
- 3.61
- Mkt cap
- 79.74M
- Vol
- 105.55K
- Avg vol
- 130.78K
- EPS
- -1.07
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.40
- High
- 3.89
- Forward P/E
- -4.25
- Beta
- 0.00
- Short ratio
- 1.53
- Inst. own
- 19.97%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 12, 2024
- 50-d avg
- 6.94
- 200-d avg
- 7.28
- 1y target
- 15.50
News
-
5 days ago benzinga.com
Coya Therapeutics To Highlight ALS Data In Poster Presentation At 2026 Annual NEALS Meeting; Co. Currently Conducts ALSTARS Trial, Phase 2/3, Study To Evaluate COYA 302 For ALS Treatment
ALS (amyotrophic lateral sclerosis) is a life-threatening neurodegenerative disease characterized by a highly variable rate of progression among affected individualsThe Company believes…
-
2 weeks ago benzinga.com
Coya Therapeutics Plans To Initiate Open-Label Extension Of Phase 2/3 ALSTARS Trial Evaluating COYA 302 For Treatment Of Amyotrophic Lateral Sclerosis
OLE planned in response to requests from ALSTARS investigators and participantsEligible participants completing 48 weeks of treatment will have the opportunity to continue receiving COYA 302Cash…
2 weeks ago businesswire.com
Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in…
2 weeks ago businesswire.com
Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in…
-
4 weeks ago benzinga.com
Coya Therapeutics Announces Full Enrollment Of Planned 120 Participants In Phase 2/3 ALSTARS Trial Evaluating COYA 302 For Potential Treatment Of Amyotrophic Lateral Sclerosis
120th participant has been enrolled in ALSTARS trial achieving target enrollmentAdditional eligible participants already in active screening will be allowed to enrollTopline data from 24-week…
4 weeks ago businesswire.com
Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in…
-
1 month ago benzinga.com
BTIG Reiterates Buy on Coya Therapeutics, Maintains $16 Price Target
BTIG analyst Thomas Shrader reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $16 price target.
-
1 month ago benzinga.com
Coya Therapeutics Enrolls 100th Participant In Phase 2/3 ALSTARS Trial Of COYA 302
Based on current screening and enrollment rates, topline data anticipated inearly Q2 2027Additional participants continue to roll over into the active extension arm of the trialCOYA 302 has received…
1 month ago businesswire.com
Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in…
-
1 month ago benzinga.com
Coya Therapeutics Announces Publication Of Preclinical Results For COYA 303 In International Journal Of Molecular Sciences; Results Show Complementary Immunomodulatory Effects In Peripheral And CNS Inflammation
Study results showed complementary immunomodulatory effects of COYA 303, a combination of proprietary low-dose IL-2 (LD-IL2) and a GLP-1 Receptor Agonist (GLP-1RA), compared to either LD-IL2 or…
1 month ago businesswire.com
Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today…
-
2 months ago benzinga.com
Roth Capital Reiterates Buy on Coya Therapeutics, Maintains $12 Price Target
Roth Capital analyst Boobalan Pachaiyappan reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $12 price target.
-
2 months ago benzinga.com
Coya Therapeutics Q2 EPS $(0.28) Beats $(0.34) Estimate, Sales $243.745K Beat $100.000K Estimate
Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.34) by 17.65 percent. This is a 22.22 percent increase over losses of…
2 months ago businesswire.com
Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in…
4 months ago zacks.com
Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year?
Here is how Coya Therapeutics, Inc. (COYA) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.
4 months ago gurufocus.com
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
[url="]Coya Therapeutics, Inc.[/url] (NASDAQ: COYA) (âCoyaâ or the âCompanyâ), a clinical-stage biotechnology company developing biologics intended to
-
4 months ago benzinga.com
Coya Therapeutics To Present Overview Of Ongoing ALSTARS Trial At European Network To Cure ALS June 24-26
Poster Title: ALSTARS: A Precision Immunomodulatory Phase 2 Trial Of Coya 302 Targeting Regulatory T Cells And Neuroinflammation In ALSAuthors: Tyrell J. Simkins, DO, PhD; Fred Grossman, DO; Stanley…
4 months ago businesswire.com
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in…
4 months ago gurufocus.com
Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease
[url="]Coya Therapeutics, Inc.[/url] (NASDAQ: COYA) (âCoyaâ or the âCompanyâ), a clinical-stage biotechnology company developing biologics intended to
4 months ago businesswire.com
Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in…
-
4 months ago benzinga.com
Coya Therapeutics Initiates Blinded Extension Phase Of Its ALSTARS Trial; Patients Who Complete The 24-Week Placebo-Controlled, Double-Blind Phase Enter The Blinded Extension Phase Of The Study
Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the initiation of the blinded…
4 months ago businesswire.com
Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces…
5 months ago benzinga.com
This Onto Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Top Wall Street analysts changed outlook for top names. See all changes on analyst ratings page. ONTO rated Buy with $350 PT by Deutsche Bank.
-
5 months ago benzinga.com
Roth Capital Initiates Coverage On Coya Therapeutics with Buy Rating, Announces Price Target of $12
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Coya Therapeutics (NASDAQ:COYA) with a Buy rating and announces Price Target of $12.
5 months ago businesswire.com
Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in…
-
5 months ago benzinga.com
Coya Therapeutics Launches $30M At-The-Market Stock Offering Agreement With Leerink Partners
On May 12, 2026, Coya Therapeutics, Inc. (the "Company") entered into a Sales Agreement (the "Sales Agreement") with Leerink Partners LLC, as sales agent ("Leerink Partners"), pursuant to which the…
-
5 months ago benzinga.com
Coya Therapeutics Q1 EPS $(0.32) Beats $(0.41) Estimate, Sales $251.147K Beat $125.000K Estimate
Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.41) by 21.95 percent. This is a 27.27 percent increase over losses of…
5 months ago businesswire.com
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in…
-
5 months ago benzinga.com
Coya Therapeutics Says FDA Grants Fast Track Designation For COYA 302, Proprietary Investigational Biologic Combination Therapy With Dual Mechanism Of Action, For ALS Treatment
Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with…
5 months ago businesswire.com
Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell…
6 months ago defenseworld.net
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Rating of “Moderate Buy” from Brokerages
Shares of Coya Therapeutics, Inc. (NASDAQ: COYA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six analysts that are covering the stock, Marketbeat reports. One…
6 months ago businesswire.com
Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces…
7 months ago businesswire.com
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in…
7 months ago businesswire.com
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces…
7 months ago businesswire.com
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in…
7 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
9 months ago benzinga.com
Coya Therapeutics Commences ~$11.1M Offering Of 2.522M Common Shares At $4.40/Share; Dr. Reddy's Laboratories And Greenlight Capital Are Investors In Offering
Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients…
10 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
1 year ago benzinga.com
Why Meta Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Why Meta Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
2 years ago benzinga.com
EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases
Coya Therapeutics is working On neurodegenerative disease treatment with its combination therapies targeting regulatory T cells. CEO Howard Berman discusses the potential of COYA 302 for ALS, FTD,…
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 201 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
During the Friday's sesion, 157 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
During Friday, 24 stocks hit new 52-week lows.